Summary
CrisprBits, founded in 2020, is developing CRISPR-based technology to create faster diagnostic tests for drug-resistant infections and other applications. The company recently raised $3 million in a pre-Series A round and operates three platforms: PathCrisp for diagnostics, EdiCrisp for gene editing, and CurieCrisp for pre-clinical work.